A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 800 participants.

Also called NCT07662044

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 800 participants (planned count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07662044
  • EU CT 2025-523936-37-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, China, Denmark, Greece, Hungary, Japan, Slovakia, South Africa, South Korea, Spain, Taiwan, Türkiye (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07662044. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-06 (actual); primary completion 2028-07-14 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
Acronym
Eluminate-1
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Elecoglipron
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Elecoglipron-matched placebo
Intervention (Drug)
Dapagliflozin-matched placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct07662044
Content hash
a3441eef5c6b66e25e292186434c627d8aba22675ad4e1511a0700c6fc5d18c4